Is Daridorexant Addictive?

If you've previously taken traditional sleeping tablets, one of your biggest concerns about another insomnia medicine may be:

“Will I become dependent on it?”

Daridorexant (Quviviq) works differently from traditional sedative-hypnotics but the answer deserves more nuance than simply saying “it's not addictive”.

What did clinical trials find?

In clinical studies of people with insomnia, there was no evidence of withdrawal symptoms indicating physical dependence when daridorexant was stopped.

A long-term extension study followed treatment for up to 12 months and similarly reported no withdrawal-related symptoms or rebound insomnia when treatment ended.

This is an important distinction from medicines such as benzodiazepines and Z-drugs, where dependence and withdrawal can become concerns during prolonged treatment.

Does daridorexant have absolutely no abuse potential?

No medicine should be described that simplistically.

The UK SmPC contains a specific section on abuse and dependence.

Although insomnia trials did not show evidence of abuse or physical dependence, a separate study in recreational drug users found drug-liking effects at doses higher than the standard recommended dose.

People with a history of alcohol or substance addiction should therefore be monitored carefully.

This distinction is important.

Low evidence of physical dependence in therapeutic insomnia studies does not mean a medicine should be treated casually.

Do I need to taper daridorexant?

According to the UK product information, daridorexant can be stopped without gradually reducing the dose.

That's different from many long-term sedative medications.

However, whether stopping treatment is clinically appropriate is still something worth discussing with your prescriber, particularly if significant insomnia symptoms remain.

How long can daridorexant be taken?

Clinical data are available for up to 12 months of continuous treatment.

The product information says treatment duration should be as short as possible, with continued treatment assessed within three months and periodically afterwards.

NICE similarly recommends stopping treatment where long-term insomnia has not responded adequately.

So “can be used longer term” should not mean “take indefinitely without review”.

How Pharmulous can help

At Pharmulous, insomnia treatment should always have an objective:

Are you falling asleep better? Staying asleep better? Functioning better the next day?

If the answer remains no, simply continuing medication isn't enough.

Our clinical team can review treatment response and whether your current insomnia plan remains appropriate.

References

1. Idorsia Pharmaceuticals UK Ltd. QUVIVIQ — Summary of Product Characteristics. eMC.
2. Kunz D et al. Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder. CNS Drugs.
3. Mignot E et al. Safety and efficacy of daridorexant. Lancet Neurology.
4. NICE. Daridorexant for treating long-term insomnia. TA922.